Prospect

Biden appointed Native Americans to top jobs at the Cabinet agency, but so far the Interior Department’s policies have been business as usual.

Today on TAP: And would that make a difference?

It’s the one way to mobilize Blacks, Hispanics, and Asians, not just white workers.

The controversy over locating a manufacturing plant could impact upcoming postal legislation, White House climate goals, and a high-profile Senate race.

The new head of the Development Finance Corporation spent two decades at a Boston hedge fund that controlled nearly $1 billion in Puerto Rican debt.

The saga of Longview Power shows the extent of private equity’s interest in coal power.

Today on TAP: One socialist gets it right. Some other socialists don’t.

It’s time for a coherent national logistics system, regulating and coordinating what has been privatized.

Building a domestic supply chain, Lordstown, Ohio, is becoming a hub for the electric-vehicle industry.

Budget airlines Frontier and Spirit, buoyed by a private equity investor, announced a merger earlier this week. But a revamped antitrust enforcement atmosphere awaits.

‘Apartheid’ is how an Amnesty International report last week characterized Israeli rule. Every group under the sun reacted, but there was no story in the Times.

Parting Shot in our February 2022 issue

Today on TAP: Biden is said to be considering Jay Shambaugh, former head of the Hamilton Project, as the Treasury’s top international official.

After a decade of flooding the market with cheap fossil fuels, investors have cut back on production.

Are investors valuing consolidation over innovation? Thrasio and its look-alikes make that a hard question to answer.

Counterfeit masks are as widely available as the real thing, outpacing the federal agencies’ ability to crack down on scammers.

How monopolization in the meatpacking and processing industry affects us all

Today on TAP: They will all probably be confirmed, but first Sen. Ben Ray Luján needs to recover to get the Dems back to 50 votes.

A decision on whether to open a costly cancer drug to generic competition will be made shortly. It doesn’t require congressional approval.

The disruptions, and the subsequent circumventions, have accelerated Amazon and Walmart’s takeover at the expense of independent retailers.